Skip to main content Back to Top
Advertisement

2/6/2023

Cisplatin Injection

Products Affected - Description

    • Cisplatin injection, Fresenius Kabi, 1 mg/mL, 100 mL vial, 1 count, NDC 63323-0103-65
    • Cisplatin injection, Fresenius Kabi, 1 mg/mL, 200 mL vial, 1 count, NDC 63323-0103-64
    • Cisplatin injection, Fresenius Kabi, 1 mg/mL, 50 mL vial, 1 count, NDC 63323-0103-51
    • Cisplatin injection, Hikma, 1 mg/mL, 100 mL vial, 1 count, NDC 00143-9505-01
    • Cisplatin injection, Hikma, 1 mg/mL, 50 mL vial, 1 count, NDC 00143-9504-01

Reason for the Shortage

    • Accord has not provided us any availability updates at this time.
    • Fresenius Kabi has ciplatin on shortage due to increased demand.
    • Hikma did not provide a reason for the shortage.
    • Teva did not provide a reason for the shortage.
    • WG Critical Care has cisplatin 1 mg/mL 200 mL vials available.

Available Products

    • Cisplatin injection, Teva, 1 mg/mL, 100 mL vial, 1 count, NDC 00703-5748-11
    • Cisplatin injection, Teva, 1 mg/mL, 50 mL vial, 1 count, NDC 00703-5747-11
    • Cisplatin injection, WG Critical Care, 1 mg/mL, 200 mL vial, 1 count, NDC 44567-0511-01

Estimated Resupply Dates

    • Fresenius Kabi has cisplatin 1 mg/mL 50 mL, 100 mL, and 200 mL vials on back order and the company estimates a release date of late-March 2023 for the 50 mL vials, mid-February 2023 for the 100 mL vials, and late-February 2023 for the 200 mL vials.
    • Hikma has cisplatin 1 mg/mL 50 mL vials on allocation. The 100 mL vials are on back order and the company estimates a release date of late-March to early-April 2023.

Updated

Updated February 6, 2023 by Michelle Wheeler, PharmD, Drug Information Specialist. Created January 10, 2023 by Leslie Jensen, PharmD, Drug Information Specialist. © 2023, Drug Information Service, University of Utah, Salt Lake City, UT.

ADVERTISEMENT

Disclaimer

Drug Shortage Bulletins are copyrighted by the Drug Information Service of the University of Utah and provided by ASHP as its exclusive authorized distributor. ASHP and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, with respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this Bulletin. Neither ASHP nor the University of Utah endorses or recommends the use of any particular drug. Any application of this information for any purpose shall be limited to personal, non-commercial use.

« Back to Drug Shortage Product Bulletins


ahfs logo

Subscribe to AHFS Clinical Drug Information to get direct access to integrated drug shortages content, plus comprehensive and actionable drug information.